Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | STK4 | Q13043 | 1/20 | 0.40 |
| ▸ | STK3 | Q13188 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600053 | 0.84 | TAAR1 (0.50) | HRH1GAAKDM4ETAAR1IDO1 | |
| SCHEMBL15974857 | 0.82 | HRH1 (0.57) | HRH1GAAKDM4EALDH1A1MPI | |
| SCHEMBL1436268 | 0.81 | LOXL2 (0.40) | HRH1GAAKDM4EALDH1A1GFER | |
| SCHEMBL3012997 | 0.79 | HRH1 (0.60) | HRH1MAOBKDM4EALDH1A1TAAR1 | |
| SCHEMBL5035220 | 0.72 | KMO (0.40) | GAATAAR1IDO1MGAMSI | |
| SCHEMBL31305506 | 0.72 | CXCR2 (0.49) | GAAKDM4EALDH1A1MPIGFER | |
| SCHEMBL28128066 | 0.72 | MAOB (0.44) | MAOBKDM4EALDH1A1TAAR1IDO1 | |
| SCHEMBL26113142 | 0.72 | CXCR2 (0.49) | GAAKDM4EALDH1A1MPIGFER | |
| SCHEMBL1435849 | 0.72 | SSTR1 (0.38) | HRH1KDM4EALDH1A1TAAR1CXCR2 | |
| SCHEMBL14692514 | 0.72 | KMO (0.55) | GAAKDM4EALDH1A1MPIGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | claimed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | claimed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | claimed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | disclosed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | disclosed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR2C, HTR3A | HRH1 39/4885MAOB 63/4885GAA 2365/4885 |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | HRH1 29/4885MAOB 60/4885GAA 2860/4885 |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | HRH1 16/4885MAOB 135/4885GAA 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.